Retroviridae (e.g., Feline Leukemia Virus, Bovine Leukemia Virus, Avian Leukosis Virus, Equine Infectious Anemia Virus, Rous Sarcoma Virus, Htlv-i, Etc.) Patents (Class 424/207.1)
-
Patent number: 7727757Abstract: Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.Type: GrantFiled: September 22, 2003Date of Patent: June 1, 2010Inventor: Adan Rios
-
Publication number: 20100104599Abstract: Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.Type: ApplicationFiled: February 22, 2008Publication date: April 29, 2010Inventors: Ryan Michael Yamka, Kim Gene Friesen, Steven Curtis Zicker
-
Patent number: 7674469Abstract: This invention is directed to a vaccine and a method for using the vaccine to protect a feline from influenza virus infection. The vaccine comprises one or more antigens from one or more H3, N8, H7 or N7-type influenza viruses.Type: GrantFiled: October 25, 2007Date of Patent: March 9, 2010Assignee: Internet International B.V.Inventors: Nallakannu P. Lakshmanan, Melissa A. Lum, Frank J. Sterner, Frederick Randal Bethke
-
Publication number: 20100047277Abstract: Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one viral surface envelope glycoprotein expressed on the surface of the virosome. The virosome can also optionally include at least one adjuvant molecule expressed on the surface of the virosome.Type: ApplicationFiled: July 12, 2007Publication date: February 25, 2010Inventors: Richard W. Compans, Chinglai Yang, Qizhi Yao, Sang-moo Kang
-
Patent number: 7662621Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: December 14, 2006Date of Patent: February 16, 2010Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Publication number: 20100028382Abstract: Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed.Type: ApplicationFiled: October 17, 2006Publication date: February 4, 2010Inventors: Pierre Charneau, Philippe Despres
-
Publication number: 20100003279Abstract: A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like.Type: ApplicationFiled: December 21, 2006Publication date: January 7, 2010Applicant: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ohta Hideyuki, Shinsuke Ezoe, Kenichi Yamazaki, Toru Kawai
-
Publication number: 20090324641Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.Type: ApplicationFiled: June 24, 2009Publication date: December 31, 2009Applicant: PFIZER INC.Inventors: Paul J. Dominowski, Ramasamy M. Mannan, Richard L. Krebs, James R. Thompson, Tedd A. Childers, Mary K. Olsen, Robert J. Yancey, Jr., Risini Weeratna, Shucheng Zhang, Cedo M. Bagi
-
Patent number: 7632509Abstract: Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo.Type: GrantFiled: July 18, 2006Date of Patent: December 15, 2009Assignee: BioSante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Debbie Farson, Jing Jing Qian
-
Patent number: 7622125Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.Type: GrantFiled: May 5, 2005Date of Patent: November 24, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan zur Megede, Susan W. Barnett
-
Publication number: 20090285901Abstract: Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.Type: ApplicationFiled: July 27, 2009Publication date: November 19, 2009Inventors: Mitsuru Akashi, Masanori Baba
-
Publication number: 20090263470Abstract: This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.Type: ApplicationFiled: May 26, 2005Publication date: October 22, 2009Inventors: Beth-Ann Coller, Veronique Henderickx, Nathalie Marie-Josephe Garcon
-
Patent number: 7604804Abstract: The present invention relates to multivalent HIV inhibitors that bind to multiple sites on a trimeric gp120 complex thereby blocking the CD4 binding site on the trimeric gp120 complex and inhibiting the attachment and entry of HIV through gp120-CD4 interactions.Type: GrantFiled: February 9, 2005Date of Patent: October 20, 2009Assignee: University of Maryland Biotechnology InstituteInventors: Lai-Xi Wang, Hengguang Li
-
Patent number: 7582302Abstract: The invention provides a novel method of vaccination of an animal of the felidae family against feline leukemia. The FeLV recombinant vaccine based on viral vector with the aid of a liquid jet needle-free injector can result in distribution of the vaccine essentially in the dermis and the hypodermis of the animal.Type: GrantFiled: June 6, 2005Date of Patent: September 1, 2009Assignee: Merial LimitedInventors: Tesfai Tseggai, Maria Camila Pardo, Alton Timothy Leard
-
Patent number: 7560117Abstract: The present invention relates to a highly processive reverse transcriptase having DNA polymerase activity and substantially reduced protease activity. More specifically, the invention relates to an isolated reverse transcriptase from foamy virus comprising a substantially inactivated protease. The invention also relates to vectors containing the gene and hosts transformed with the vector of the invention. Further, the invention relates to a method for producing reverse transcriptase having DNA polymerase activity and substantially reduced protease activity by expressing the reverse transcriptase genes of the present invention in a recombinant host. Methods are also provided for producing cDNA from polynucleotides using the highly processive reverse transcriptase of the invention. Kits for the preparation of cDNA from RNA comprising the highly processive reverse transcriptase of the invention are also provided.Type: GrantFiled: May 22, 2002Date of Patent: July 14, 2009Assignee: Fred Hutchinson Cancer Research CenterInventors: Stephen Hughes, Paul Boyer, Maxine Linial, Carolyn Stenbak, Patrick Clark
-
Publication number: 20090175902Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: June 27, 2006Publication date: July 9, 2009Inventors: Haixiang Lin, Lie Tao Victor Li
-
Publication number: 20090169503Abstract: This invention provides DNA vaccines for the treatment of patients undergoing retroviral therapy. The vaccines are surprisingly effective at controlling viremia.Type: ApplicationFiled: July 11, 2005Publication date: July 2, 2009Applicant: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF DEPT OF H&HSInventors: Barbara K. Felber, George N. Pavlakis
-
Patent number: 7544670Abstract: The present invention provides methods and compositions useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3 and/or HoxB3. In addition, the present invention provides methods and compositions for improved wound healing in subjects having impaired healing capabilities, such as diabetic and aged subjects.Type: GrantFiled: December 29, 2006Date of Patent: June 9, 2009Assignee: The Regents of the University of CaliforniaInventors: Nancy Boudreau, David M. Young, Cornelia Myers
-
Publication number: 20090123495Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.Type: ApplicationFiled: August 8, 2006Publication date: May 14, 2009Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
-
Patent number: 7514233Abstract: The present invention provides integrase interacting proteins including cofactors which promote strand transfer activity of viral integrase, more particularly HIV integrase, and methods and uses relating thereto. The present invention also relates to methods of identifying molecules interacting with integrase interacting protein and their use as an antiviral.Type: GrantFiled: September 26, 2003Date of Patent: April 7, 2009Assignee: K.U. Leuven Research & DevelopmentInventors: Zeger Debyser, Petr Cherepanov, Erik De Clercq
-
Publication number: 20090060947Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: May 18, 2007Publication date: March 5, 2009Applicant: SANOFI PASTEUR, INC.Inventors: James Tartaglia, Alexander Harari, Giuseppe Pantaleo
-
Publication number: 20090041852Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.Type: ApplicationFiled: March 15, 2007Publication date: February 12, 2009Applicant: UNIVERSITEIT GENTInventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie
-
Publication number: 20090041804Abstract: The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of Tell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells.Type: ApplicationFiled: March 21, 2007Publication date: February 12, 2009Applicant: The Gov. of the USA, as represented by Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Dennis Panicali
-
Patent number: 7488485Abstract: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3? LTR.Type: GrantFiled: September 15, 2004Date of Patent: February 10, 2009Assignee: University of Kansas Medical CenterInventors: Opendra Narayan, Zhenqian Liu
-
Patent number: 7476517Abstract: The invention relates to virus like particles, their preparation and their use in pharmaceutical screening and functional genomics. The invention further provides a variety of assay formats to be used with said virus like particles.Type: GrantFiled: December 30, 2004Date of Patent: January 13, 2009Assignee: Evotec AGInventor: Nicholas Hunt
-
Publication number: 20090012494Abstract: The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.Type: ApplicationFiled: November 29, 2007Publication date: January 8, 2009Applicant: NanoPass Technologies Ltd.Inventors: Yehoshua Yeshurun, Yotam Levin, Yotam Almagor, Gilad Lavi, Meir Hefetz, Yoel Sefi, Richard Ian Catchpole
-
Patent number: 7470777Abstract: Embodiments of the invention include compositions comprising and methods utilizing a retroviral integrase complex comprising a recombinant integrase having a domain comprising a non-native protein binding site, and a DNA binding protein comprising a DNA binding domain and a peptide binding domain that binds the non-native protein binding site of the recombinant integrase.Type: GrantFiled: December 22, 2005Date of Patent: December 30, 2008Assignees: Iowa State University Research Foundation, Inc., University of Iowa Research FoundationInventors: Paul B. McCray, Jr., Patrick L. Sinn, Daniel F. Voytas, Junbiao Dai
-
Publication number: 20080317780Abstract: The invention relates to a viral vaccine, especially a retroviral vaccine, and methods of forming such a vaccine. The vaccine is formed from a whole-killed virus suspension in a cell lysate or culture medium, wherein the virus is killed by exposure to a chloramine compound at a level adequate to inactivate zinc finger proteins. The chloramine compound may be taurine chloramine, adenosine chloramine, phenylalanine chloramine, and alanine chloramine. The vaccine may be used as a prophylactic or therapeutic vaccine and may be developed from a subject's own strains of virus so as to be considered an autologous vaccine.Type: ApplicationFiled: October 26, 2007Publication date: December 25, 2008Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Henry FLISS, Anil DUDANI
-
Publication number: 20080299150Abstract: A method for processing immuno-competent cells in view of an antiviral therapy on a human or animal subject, includes: a step for collecting immuno-competent cells on the human or animal subject, and a step for processing the collected immuno-competent cells, so as to stimulate at least a part of the immuno-competent cells, by presenting a muted viral particle to the cells, in view of a reinjection of the stimulated cells into the human or animal subject.Type: ApplicationFiled: May 2, 2008Publication date: December 4, 2008Applicant: SANKHIA CORPORATIONInventors: Patrick Rambaud, Jean-Pierre Lablanchy
-
Publication number: 20080286295Abstract: The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation of a complex between the recombinant antigen and the antibody and (b) detecting the presence or absence of the complex, wherein presence or absence of a complex is indicative of the immune status of the animal. Preferably such a method indicates whether the animal should be vaccinated. The present invention also includes an assay comprising (a) a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent; and (b) a means to detect an antibody that selectively binds to the recombinant antigen.Type: ApplicationFiled: May 29, 2008Publication date: November 20, 2008Inventors: Wayne A. Jensen, Michael R. Lappin, David K. Rosen, Janet S. Andrews
-
Publication number: 20080260775Abstract: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the same to a subject.Type: ApplicationFiled: February 15, 2006Publication date: October 23, 2008Inventors: Robert E. Johnston, Philip R. Johnson
-
Patent number: 7427468Abstract: The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101 antibodies.Type: GrantFiled: October 1, 2003Date of Patent: September 23, 2008Assignee: Functional Genetics, Inc.Inventor: Limin Li
-
Publication number: 20080226674Abstract: The present invention is intended to provide a pharmaceutical composition for delivering a chemotherapeutic, preferably an anticancer drug, into cells or into a living organism, using a viral envelope vector, and provides a pharmaceutical composition comprising a chemotherapeutic encapsulated in, or used in combination with, a viral envelope vector having an adjuvanticity as an active ingredient. Thereby it is possible to introduce an anticancer drug encapsulated in a viral envelope vector directly into a tumor, with coadministration of another anticancer drug so as to induce tumor cell-specific antitumor immunity also thanks to the adjuvant action of HVJ-E, and hence to regress the tumor. The present invention also provides a pharmaceutical composition comprising a viral envelope vector and a chemotherapeutic as active ingredients.Type: ApplicationFiled: March 31, 2005Publication date: September 18, 2008Applicants: Genomldea Inc., AnGesMG, Inc.Inventors: Hitoshi Kotani, Yasufumi Kaneda, Hirokazu Kawano, Masayuki Fukumura, Masayuki Kurooka
-
Publication number: 20080220015Abstract: Disclosed is a method of modulating neutralizing antibodies formation against a heterologous protein. The method may be used to induce tolerance of the immune system towards the protein, such tolerance being useful to allow long-term gene therapy or transgene expression. The method may also be used to provide an animal with a reproducible functional inactivation phenotype of an endogenous protein of the animal.Type: ApplicationFiled: March 10, 2008Publication date: September 11, 2008Applicant: NOKAD, S.A.Inventor: Amine ABINA
-
Publication number: 20080181912Abstract: The invention relates to feline IGF-1, to the nucleotide sequence encoding this protein and to the use of IGF-1 as adjuvant for the vaccination of cats, in particular against the feline retroviruses FIV and FeLV. IGF-1 may be used in the form of protein or may be expressed in vivo by a suitable, e.g. viral or plasmid, expression vector. The invention relates to all types of vaccines, namely inactivated, attenuated, sub-unit and recombinant vaccines. The vectors expressing IGF-1 in vivo may also be used in immunity-stimulating compositions.Type: ApplicationFiled: December 21, 2007Publication date: July 31, 2008Inventor: Christine Michele Pierrette ANDREONI
-
Patent number: 7405292Abstract: This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products.Type: GrantFiled: February 14, 2005Date of Patent: July 29, 2008Assignee: The Children's Hospital of PhiladelphiaInventors: Terri H. Finkel, Jiyi Yin
-
Patent number: 7399473Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of a co-receptor present on the cell. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CD4 D1D2 and CD4M9 sequences.Type: GrantFiled: May 6, 2005Date of Patent: July 15, 2008Assignee: University of Maryland Biotechnology InstituteInventors: Anthony Louis Devico, Timothy R. Fouts, Robert G. Tuskan
-
Patent number: 7381817Abstract: The invention relates to: a nucleotide fragment of an MSRV-1 LTR-RU5 region, comprising a nucleotide sequence encoding the expression of a protein, wherein the protein comprises a peptide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4; complementary nucleotide fragments; probes and primers that hybridize to the fragment; proteins encoded by the fragment; antibodies directed against the proteins encoded by the fragment; and processes for detecting the presence of MSRV-1 using a probe or an antibody of the invention.Type: GrantFiled: August 11, 2003Date of Patent: June 3, 2008Assignee: Bio MerieuxInventors: Glaucia Paranhos-Baccala, Herve Perron, Florence Komurian-Pradel
-
Publication number: 20080118530Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: ApplicationFiled: October 7, 2005Publication date: May 22, 2008Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Patent number: 7329486Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: GrantFiled: March 30, 2004Date of Patent: February 12, 2008Assignee: The Board of Regents of the University of Texas SystemInventors: Robert A. Davey, Andrey Kolokoltsov
-
Patent number: 7285271Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.Type: GrantFiled: May 31, 1995Date of Patent: October 23, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Paul A. Luciw, Dino Dina
-
Patent number: 7279168Abstract: The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline CD28 protein or an immunogenic portion thereof, a feline cD80 protein or an immunogenic portion thereof, a feline CD86 protein or an immunogenic portion thereof, or a feline CTLA-4 protein or an immunogenic portion thereof. The protein is capable of being expressed when the recombinant virus is introduced into an appropiate host. The present invention also involves a recombinant virus further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen. The present invention also comprises recombinant viruses which are capable of enhancing an immune response in a feline.Type: GrantFiled: April 30, 1999Date of Patent: October 9, 2007Assignees: Texas A & M University System, Schering-Plough Animal Health CorporationInventors: Barbara J. Winslow, Mark D. Cochran, Stephen Hash, Insoo Choi, Ellen Collisson
-
Patent number: 7267824Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.Type: GrantFiled: April 7, 2003Date of Patent: September 11, 2007Assignee: University of Florida Research Foundation, Inc.Inventor: Janet K. Yamamoto
-
Patent number: 7232899Abstract: The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.Type: GrantFiled: January 14, 2000Date of Patent: June 19, 2007Assignee: The Scripps Research InstituteInventors: Daniel J. Von Seggern, Glen R. Nemerow
-
Patent number: 7229625Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.Type: GrantFiled: April 22, 2005Date of Patent: June 12, 2007Assignee: Sanofi Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 7223409Abstract: This invention relates to the development of a mammalian expression vector, under which expression of the structural genes of western equine encephalitis virus have been placed under the control of an eucaryotic promoter. When the recombinant vector is administered to mammalian cell culture or using a cell-free transcription/translation system, in vitro, authentic structural proteins of western equine encephalitis virus are produced as verified by reactivity with monoclonal antibodies developed to western equine encephalitis virus. When the recombinant DNA molecule is administered in vivo, a protective immune response is induced, thereby enhancing protection of the individual against subsequent infection by western equine encephalitis virus. In a similar manner, DNA vaccines to related alphaviruses (Venezuelan and eastern equine encephalitis viruses) could also be developed.Type: GrantFiled: August 20, 2004Date of Patent: May 29, 2007Assignee: The Minister of National Defence, Government of CanadaInventors: Leslie P. Nagata, Jonathon P. Wong
-
Patent number: 7202079Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 10, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7198793Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 3, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7169391Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: August 10, 2005Date of Patent: January 30, 2007Assignee: Smithkline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 7157439Abstract: The present invention provides methods and compositions useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3 and/or HoxB3. In addition, the present invention provides methods and compositions for improved wound healing in subjects having impaired healing capabilities, such as diabetic subjects.Type: GrantFiled: December 23, 2003Date of Patent: January 2, 2007Assignee: The Regents of the University of CaliforniaInventors: Nancy Boudreau, David M. Young, Cornelia Myers